Pharma sales growth slowed to 11.9% in 2012-13
Updated: Apr 17, 2013 05:01:55pm
New Delhi, Apr 17 (KNN) Sale of pharma products to retailers slipped to 11.9 per cent in 2012-13 as compared to 15.8 per cent last year, said a media report attributing to the data compiled by research firm AIOCD AWACS.
During the first half of the fiscal, the sale was good but the demand for drugs declined in the latter half of the fiscal, especially those drugs meant for chronic diseases such as diabetes.
Barring anti-malarial, the growth pace of drugs catering to most other therapies either stagnated or declined in 2012-13, against the previous year, the media report said.
Also, the sale of drugs for treatment of respiratory ailments, pain, gynaecological disorders and seasonal infections slowed in 2012-13.
For instance, respiratory drug sales grew at a slow 8.4 per cent last year. Similarly, anti-infective drugs which constitute 18 per cent of the industry grew at a lacklustre 9.8 per cent, according to the report.
However, the demand for some therapies such as the hormone supplements, sex stimulants and anti-malarial drugs grew ahead of the industry in 2012-13.
According to the report, among the listed pharma companies, Cadila’s sales rose the most (20.8 per cent) in 2012-13. Sun Pharma (20.2 per cent) and Glenmark (18.9 per cent) figured among the most consistent performers, clocking robust growth during the same period. Merck and JB Chemicals also witnessed a pick-up in growth.
AstraZeneca Pharma, Orchid Pharma and Strides topped the loser’s list, posting sales declines of 20.6 per cent, 9.6 per cent and 8.1 per cent respectively for the year. Other listed companies that grew slower than industry include Piramal Healthcare (3.7 per cent growth), Elder Pharma (5.1 per cent) and Wockhardt (5.5 per cent). (KNN)
During the first half of the fiscal, the sale was good but the demand for drugs declined in the latter half of the fiscal, especially those drugs meant for chronic diseases such as diabetes.
Barring anti-malarial, the growth pace of drugs catering to most other therapies either stagnated or declined in 2012-13, against the previous year, the media report said.
Also, the sale of drugs for treatment of respiratory ailments, pain, gynaecological disorders and seasonal infections slowed in 2012-13.
For instance, respiratory drug sales grew at a slow 8.4 per cent last year. Similarly, anti-infective drugs which constitute 18 per cent of the industry grew at a lacklustre 9.8 per cent, according to the report.
However, the demand for some therapies such as the hormone supplements, sex stimulants and anti-malarial drugs grew ahead of the industry in 2012-13.
According to the report, among the listed pharma companies, Cadila’s sales rose the most (20.8 per cent) in 2012-13. Sun Pharma (20.2 per cent) and Glenmark (18.9 per cent) figured among the most consistent performers, clocking robust growth during the same period. Merck and JB Chemicals also witnessed a pick-up in growth.
AstraZeneca Pharma, Orchid Pharma and Strides topped the loser’s list, posting sales declines of 20.6 per cent, 9.6 per cent and 8.1 per cent respectively for the year. Other listed companies that grew slower than industry include Piramal Healthcare (3.7 per cent growth), Elder Pharma (5.1 per cent) and Wockhardt (5.5 per cent). (KNN)
Loading...
